FindTrial
Sign In

Clinical observation of two regimens of bismuth agents combined with quadruple therapy for the treatment of Helicobacter pylori infection.

Clinical observation of two regimens of bismuth agents combined with quadruple therapy for the treatment of Helicobacter pylori infection.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118634
Enrollment
Unknown
Registered
2026-02-09
Start date
2025-10-01
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Amoxicillin Clarithromycin group:None
Metronidazole Tetracycline group:None

Sponsors

The University of Hong Kong Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years old; 2. Positive 13C urea breath test (13C-UBT); 3. No previous H. pylori eradication therapy.

Exclusion criteria

Exclusion criteria: 1. Individuals allergic to the drugs used in this study; 2. Individuals with severe organ diseases; 3. Individuals with malignant tumors; 4. Women who are pregnant or breastfeeding; 5. Individuals who have used antibiotics or bismuth preparations within the past 4 weeks; 6. Individuals who have used acid-suppressing drugs within the past 2 weeks (such as PPIs, H2 receptor antagonists, or new potassium-competitive acid blockers).

Design outcomes

Primary

MeasureTime frame
Hp eradication rate;—

Secondary

MeasureTime frame
Incidence of adverse reactions;—

Countries

China

Contacts

Public ContactShaowei Han

The University of Hong Kong Shenzhen Hospital

hansw@hku-szh.org+86 755 86913333

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026